Alan Dunton - May 17, 2023 Form 4/A - Amendment Insider Report for CorMedix Inc. (CRMD)

Role: Director
Signature: /s/ Alan W. Dunton
Stock symbol: CRMD
Transactions as of: May 17, 2023
Transactions value $: $12,980
Form type: 4/A - Amendment
Date filed: 5/18/2023, 05:05 PM
Date Of Original Report: May 17, 2023
Previous filing: Jan 18, 2023
Next filing: Jun 22, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRMD	Common Stock	Purchase	$13K	+3K	+48%	$4.33	9.25K	May 17, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.34, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.

Content

On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.34, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.